• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

Recent Advances in the Study of Zinc,bromo(3-methyl-2-thienyl)- (9CI) (CAS: 312693-45-1) in Chemical Biology and Pharmaceutical Research

The compound Zinc,bromo(3-methyl-2-thienyl)- (9CI) (CAS: 312693-45-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential applications in drug development. The compound, characterized by its zinc-bromide-thienyl structure, has shown promise in various biochemical pathways, making it a subject of intense study among researchers.

Recent studies have highlighted the role of Zinc,bromo(3-methyl-2-thienyl)- (9CI) in modulating enzyme activity, particularly in metalloenzymes where zinc plays a critical role. For instance, research published in the Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits inhibitory effects on certain zinc-dependent hydrolases, which are implicated in inflammatory diseases. The study utilized X-ray crystallography to elucidate the binding mechanism, revealing a unique interaction between the bromo-thienyl moiety and the enzyme's active site. These findings suggest potential applications in designing novel anti-inflammatory agents.

In addition to its enzyme-modulating properties, Zinc,bromo(3-methyl-2-thienyl)- (9CI) has been investigated for its antimicrobial activity. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibited potent activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to disrupt bacterial cell membrane integrity, a mechanism distinct from traditional antibiotics. This discovery opens new avenues for developing antimicrobial agents with reduced resistance potential.

The synthesis and optimization of Zinc,bromo(3-methyl-2-thienyl)- (9CI) have also been a focus of recent research. A team from the University of Cambridge developed a novel catalytic method for its synthesis, as detailed in Angewandte Chemie (2023). This method employs a palladium-catalyzed cross-coupling reaction, significantly improving yield and purity compared to traditional approaches. Such advancements in synthesis are critical for scaling up production and facilitating further pharmacological studies.

Despite these promising developments, challenges remain in the clinical translation of Zinc,bromo(3-methyl-2-thienyl)- (9CI). Issues such as bioavailability, toxicity, and stability under physiological conditions need to be addressed. Ongoing research is exploring prodrug strategies and nanoformulations to overcome these hurdles. For example, a recent preprint on bioRxiv (2024) described a lipid-based nanoparticle delivery system that enhances the compound's solubility and targeted delivery to inflamed tissues.

In conclusion, Zinc,bromo(3-methyl-2-thienyl)- (9CI) (CAS: 312693-45-1) represents a versatile scaffold with significant potential in drug discovery. Its unique chemical properties and diverse biological activities make it a valuable candidate for further investigation. Future research should focus on optimizing its pharmacokinetic profile and exploring its therapeutic potential in various disease models, including cancer and neurodegenerative disorders.

• 84815-06-5(Lithium, (4-methyl-2-thienyl)-)
• 108343-10-8(3-Methylthiophene-d3)
• 133374-03-5(Lithium 3-methylthiophen-2-ide)
• 583855-46-3(Lithium 3,4-dimethylthiophen-2-ide)
• 632-15-5(3,4-Dimethylthiophene)
• 95184-07-9(Magnesium,bromo(3-methyl-2-thienyl)-)
• 25879-27-0(Methyl, 3-thienyl-)
• 115149-44-5(Methylene, 3-thienyl-)
• 84928-92-7(Thiophene, 3-methyl-,homopolymer)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)